The expanding role of H1 antihistamines: A patent survey of selective and dual activity compounds 2005 2010

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 9, 2010, Pages 1197-1218

  Beaton, Graham ^a   Moree, Wilna J ^a  

^a NONE

Author keywords

5 HT2A receptor; Allergic disease; CCR3 receptor; H1 antihistamines; H1 receptor; H3 receptor; Inflammatory disease; Insomnia; Pruritis

Indexed keywords

1 [3 (10,11 DIHYDRO 5H DIBENZO[A,D]CYCLOHEPTEN 5 YLIDENE)PROPYL] 3 PIPERIDINECARBOXYLIC ACID; ANTIHISTAMINIC AGENT; ASTEMIZOLE; AZD 1744; AZD 3778; AZETIDINE; BEPREVE; BETOTASTINE; CETIRIZINE; DEXCHLORPHENIRAMINE; DIPHENHYDRAMINE; DOXEPIN; EBASTINE; ESZOPICLONE; FEXOFENADINE; GSK 1004723; GSK 835726; HY 2901; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; OLANZAPINE; OLOPATADINE; PHENIRAMINE; RUPATADINE; TEMAZEPAM; TERFENADINE; TRIPROLIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 344484; ZOLPIDEM; ANTIALLERGIC AGENT; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HYPNOTIC SEDATIVE AGENT;

ALLERGY; ANTIINFLAMMATORY ACTIVITY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; HEALTH SURVEY; HUMAN; INSOMNIA; LOW DRUG DOSE; NONHUMAN; REVIEW; SLEEP DISORDER; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION; ANIMAL; DRUG DESIGN; DRUG EFFECT; HYPERSENSITIVITY; METABOLISM; PATENT; PATHOPHYSIOLOGY;

ANIMALS; ANTI-ALLERGIC AGENTS; DRUG DESIGN; HISTAMINE H1 ANTAGONISTS; HUMANS; HYPERSENSITIVITY; HYPNOTICS AND SEDATIVES; PATENTS AS TOPIC; RECEPTORS, HISTAMINE H1; SLEEP INITIATION AND MAINTENANCE DISORDERS;

EID: 77955834725     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.510516     Document Type: Review

References (143)

1. Akdis CA, Blaser K. Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 2003;112(1):15-22
2. Berger WE. Overview of allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:7-12
3. Bousquet J, van Cauwenberge P, Khaltaev N, et al.; In collaboration with the World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5):S147-334
4. Raffa RB. Antihistamines as analgesics. J Clin Pharm Ther 2001;26:81-85
5. Lin J-S, Hou Y, Sakai K, Jouvet M. Histamine descending inputs to the Mesopontine Tegmentum and their role in the cortical activation and wakefulness in the cat. J Neurosci 1996;16:1523-1537
6. 1-receptors: localization and role in airway physiology and in immune functions. J Allergy Clin Immunol 2003;112(4):S60-8
7. 1-antihistamines: more relevant than ever in the treatment of allergic disorders. J Allergy Clin Immunol 2003;112(4):S42-52
8. 1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008;7:41-53
9. Bakker RA, Timmerman H, Leurs R. Histamine receptors: specific ligands, receptor biochemistry, and signal transduction. Clin Allery Immunol 2002;17:27-64
10. 1-mediated phospholipase C and adenylyl cyclase signaling. J Pharmacol Exp Ther 2004;311:274-281
11. 1 receptor antagonists. Eur J Pharmacol 2000;387(1):R5-7
12. Staub AM, Bovet D. Actions de la thymoethyl-diethylamine (929F) et des ethers phenoliques sur le chocanaphylactique de cobaye. CRSoc Biol 1937;128:818-825
13. Meolie AL, Rosen C, Kristo D, et al. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin Sleep Med 2005;1:173-187
14. 1 receptor induces cytosolic calcium increase and aquaporin translocation in human salivary gland cells. JPET 2009;330:403-412
15. Van-Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000;55(2):116-134 (Pubitemid 30106016)
16. Dubuske LM. Second-generation antihistamines: the risk of ventricular arrhythmias. Clin Ther 1999;21(2):281-295
17. Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996;385(1-2):77-80
18. Renwick AG. The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy 1999;29(Suppl 3):116-124
19. Holgate ST, Canonica GW, Simons FE, et al. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003;33(9):1305-1324
20. Singh-Franco D, Ghin HL, Robles GI, et al. Levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children. Clin Ther 2009;31(8):1664-1687
21. Kalogeromitros D, Kempuraj D, Katsarou-Katsari A, et al. Theophylline as 'add-on' therapy to cetirizine in patients with chronic idiopathic urticaria. A randomized, double-blind, placebo-controlled pilot study. Int Arch Allergy Immunol 2006;139(3):258-264
22. 1 antagonist chlorpheniramine. Bioorg Med Chem Lett 2003;13:1959-1961
23. 3 receptor blockade on cutaneous microvascular permeability elicited by compound 48/80. Life Sci 2005;76:1787-1794
24. 1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasation. Eur J Pharmacol 2005;506:265-271
25. Arias K, Baig M, Colangelo M, et al. Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. J Allergy Clin Immunol 2009;124(2):307-314
26. 1 receptor. Eur J Pharmacol 2007;563:224-232
27. 1-antagonist on symptoms and eosinophilic inflammation in allergic rhinitis. Respir Res 2010;11:17
28. Scannell RT, Differding E, Talaga P. Dual acting antihistaminergic agents. Mini Rev Med Chem 2004;4:923-933
29. 1-receptor agonists and antagonists with the human histamine H4-receptor. Mol Pharmacol 2009;76(5):1019-1030
30. Metz M, Scholz E, Ferran M, et al. Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. Ann Allergy Asthma Immunol 2010;104:86-92
31. Brockman HL, Momsen MM, Knudtson JR, et al. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul Immunol Inflamm 2003;11:247-268
32. Leonardi A, Quintieri L. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Expert Opin Pharmacol 2010;11:969-981
33. 1 receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models. Exp Eye Res 2010;91:85-91
34. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1mg, 3mg, and 6mg in adults with primary insomnia. Sleep 2007;30:1555-1561
35. 1-antihistamines for clinical evaluation in the treatment of insomnia. J Med Chem 2009;52:5307-5310
36. 1 antagonists after an oral and intravenous microdose to human subjects. Br J Clin Pharmacol 2009;67:288-298
37. Hall H, Sallemark M, Wedel I. Acute effects of atypical antidepressants on various receptors in the rat brain. Acta Pharmacol Toxicol 1984;54:379-384
38. Teegarden BR, Shamma HA, Xiong Y. 5-HT2A inverse agonists for the treatment of insomnia. Curr Top Med Chem 2008;8:969-976
39. 1 receptor in pain perception: a study of the receptor gene knockout mice. Eur J Pharmacol 2000;391:81-89
40. Olsen UB, Eltorp CT, Ingvardsen BK, et al. ReN 1869, a novel tricyclic antihistamine, is active against neurogenic pain and inflammation. Eur J Pharmacol 2002;435:43-57
41. Dray A. Novel molecular targets in pain control. Curr Opin Anaesthesiol 2003;16:521-525
42. Erfanparast A, Tamaddonfard E, Farshid AA, Khalilzadeh E. Effect of microinjection of histamine into the dorsal hippocampus on the orofacial formalin-induced pain in rats. Eur J Pharmacol 2010;627:119-123
43. 3 and H4 receptors as novel drug targets. Expert Opin Invest Drugs 2009;18:1519-1531
44. Liu H, Altenbach RJ, Carr TL, et al. cis-4-(Piperazin-1-yl)-5,6,7a,8,9, 10,11,11a-octahydrobenzofuro[2,3-h] quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. J Med Chem 2008;51:7094-7098
45. Hasanein P. Two histamine H2 receptor antagonists, zolantidine and cimetidine, modulate nociception in cholestatic rats. J Psychopharmacol 2009; doi:10.1177/0269881109106912
46. Chong CR, Chen X, Shi L, et al. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol 2006;2:415-416
47. Musonda CC, Whitlock GA, Witty MJ, et al. Chloroquine-astemizole hybrids with potent in vitro and in vivo antiplasmodial activity. Bioorg Med Chem Lett 2009;19:481-484
48. Elan Pharma Int. Nanoparticulate corticosteroid and antihistamine formulations. WO2006102494; 2006
49. Nektar Therapeutics. Oligomer-antihistamine conjugates. WO2008112257; 2008
50. Biolipox. Antihistamine-and corticosteroid-containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders. WO2007026151; 2007
51. 1-antihistamines: patent highlights 2000 -2005. Expert Opin Ther Pat 2006;16:109-117
52. Terada N, Hamano N, Kim WJ, et al. The kinetics of allergen-induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa. Am J Respir Crit Care Med 2001;164:575-579
53. Humbles AA, Lu B, Friend DS, et al. The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc Natl Acad Sci USA 2002;99:1479-1484
54. Ying S, Meng Q, Zeibecoglou K, et al. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and non-atopic (intrinsic) asthmatics. J Immunol 1999;163:6321-6329
55. Lilly CM, Nakamura H, Belostotsky OI, et al. Eotaxin expression after segmental allergen challenge in subjects with atopic asthma. Am J Respir Crit Care Med 2001;163:1669-1675
56. Willems LI, Ijzerman AP. Small molecule antagonists for chemokine CCR3 receptors. Med Res Rev 2009; doi: 10.1002/med.20181
57. Novartis. Azetidine derivatives as CCR-3 receptor antagonists. WO2003077907; 2003
58. Novartis. 1,3-disubstituted azetidine derivatives as CCR-3 receptor antagonists in the treatment of inflammatory and allergic diseases. WO2005026113; 2005
59. Yamanouchi. Preparation of N-[1-(6-fluoronaphthalen-2-ylmethyl) pyrrolidin-3-yl]urea derivatives as CCR3 inhibitors. WO2003072545; 2003
60. Yamanouchi. Preparation of (N-pyrrolidinyl)acrylamide derivatives as CCR3 antagonists for treatment of asthma. WO2004022535; 2004
61. 1 mediated disease state. WO2004085423; US2006281726; 2004
62. Astrazeneca. A preparation of (piperidinylmethyl)piperidine derivatives, useful for the treatment of chemokine mediated diseases. WO2004087659; US2007032523; US2009118513; 2004
63. Astrazeneca. Piperdine derivatives for the treatment of chemokines mediated disease. WO2005097775; US20080262037; 2005.
64. Astrazeneca. Piperidine derivatives useful as modulators of chemokine receptor activity. WO2003004487; 2003
65. Astrazeneca. Preparation of pharmaceuticals salts of [1,4] bipiperidine. WO2005044268; US2007276141; 2005
66. Astrazeneca. Preparation of piperidinylmethylpiperidines for the treatment of chemokine mediated diseases. WO2006126947; US20080275084;.2006.
67. Astrazeneca. Preparation of novel piperidine derivatives for treatment of chemokine mediated diseases. WO2007011293; 2007
68. Bryan SA, Jose PJ, Topping JR, et al. Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists. Am J Respir Crit Care Med 2002;165:1602-1609
69. Astrazeneca. Preparation of piperidine derivatives for the treatment of chemokine mediated diseases. WO2006126948; US20080200505; 2006
70. Astrazeneca. Preparation of piperidines as chemokine modulators for treatment of asthma and related diseases. WO20050073192; US2007054924;2005
71. 1 receptor antagonists. WO2007114770; US20080108661; 2007
72. Available from. http://www.astrazenecacom/mshost3690701/content/ resources/media/investors/ 2006-business-review-john.pdf [Accessed 22 May 2010]
73. Taylor JD, Wreggett KA, Olssen H, Sjorbring U. Latest therapies targeting exacerbations in COPD. Drug Discov Today Ther Strateg 2008;5:101-110
74. 3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin Invest Drugs 2007;16:967-985
75. 3 receptor activation inhibits neurogenic sympathetic vasoconstriction in porcine nasal mucosa. Eur J Pharmacol 2002;452:339-345
76. 3 receptors in human nasal mucosa inhibits sympathetic vasoconstriction. Eur J Pharmacol 2004;484:83-89
77. 3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. Am J Rhinol 1999;13:91-399
78. Taylor-Clark T, Sodha R, Warner B, Foreman J. Histamine receptors that influence blockage of the normal human nasal airway. Br J Pharmacol 2005;144:867-874
79. Available from:http://www.scribd.com/doc/13937992/GlaxoSmithKline-Drug- RD-Pipeline-Feburary-2009. [Accessed 22 May 2010].
80. Available from: http://www.gsk.com/financial/pp-pipeline-standard.htm. [Accessed 22 May 2010].
81. Glaxo Group. Preparation of 1-{4-[(1-Cyclobutyl-4-piperidinyl)oxy] phenyl}-{[4(methylsulfonyl)phenyl] carbonyl}piperazine or a derivative thereof for use in treating inflammation or allergies. US20060019964; 2006
82. 1 receptor antagonist for treatment of allergic rhinitis. WO2006125665; US20060293298; 2006
83. Glaxo Group. 1-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}-4-{[4- (methylsulfonyl)phenyl]carbonyl} piperazine or a derivative thereof. US20060019964; 2006
84. Glaxo Group. Preparation of 1-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl} -4-{[4-(methylsulfonyl)phenyl]carbonyl} piperazine or a derivative thereof for use in treating inflammation or allergies. WO2006090142; 2006
85. 3 antagonist for treating allergic rhinitis: a development candidate? Glaxo Group Ltd: WO2006090142. Expert Opin Ther Patents 2007;17(4):449-452
86. 3 antagonists for the treatment of inflammatory and/or allergic disorders. WO2007071691; US20080312280; 2007
87. 3 antagonists and their preparation, pharmaceutical compositions and use in the treatment of allergic diseases. WO2007122156; US20090105225; US20080039444; 2007
88. Glaxo Group. Combination of fluticasone furoate with 4-[(4-chlorophenyl) methyl]-2-({(2R)-1-[4-(4-{[3-(hexahydro-1H-azepin-1-yl)propyl] oxy}phenyl)butyl]-2-pyrrolidinyl}methyl)-1(2H)-phthalazinone. WO2009050159;2009
89. Available from: ct2/show/NCT00824356 [Accessed 22 May 2010]
90. Glaxo Group. Phthalazinone derivatives, processes for preparing them, pharmaceutical compositions containing them, and their use in the treatment of allergic rhinitis and/or other diseases. WO2008074803; 2008
91. 1 receptor antagonists for treatment of inflammatory and allergic diseases. WO2009047336; 2009
92. 1 receptor antagonist for treatment of inflammatory and allergic disorders. WO20090150101; 2009
93. Glaxo Group. Compounds. US20090270355; 2009
94. Glaxo Group. Preparation of quinolinyloxypiperidine and pyrrolidine derivatives for the treatment of inflammatory and allergic diseases of the respiratory tract. WO2009021965; 2009
95. 1 receptor antagonists for treatment of inflammatory and allergic diseases. WO2009050204; 2009
96. Glaxo Group. Histamine receptor antagonists comprising an azepin core. WO2007135081; 2007
97. Sumitomo. Preparation of uracil carboxylic acid derivatives as antiallergic agents. JP2007176851; 2007
98. 1 antagonists. Bioorg Med Chem Lett 2009;19:2766-2771
99. 1 receptor antagonism effect. US2009082373; 2009
100. Nippon Zoki Pharmaceuticals. Preparation of piperidine derivatives as histamine receptor antagonists. WO2009096080; 2009
101. Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: a meta analysis of risks and benefits. Br Med J 2005;331:1169-1175
102. Vermeeren A. Residual effects of hypnotics. CNS Drugs 2004;18:297-328
103. Barbier AJ, Bradbury MJ. Histaminergic control of sleep wake cycles: recent therapeutic advances for sleep and wake disorders. CNS Neurol Disord Drug Targets 2007;6:31-43
104. Kay GG, Plotkin KE, Quig MB, et al. Sedating effects of AM/PM antihistamine dosing with evening chlorpheniramine and morning terfenadine. Am J Manag Care 1997;3:1843-1848
105. 1-antagonism, while objectively and subjectively measured sedation is increased. Eur Neuropsychopharmacol 2010; doi:10.1016/j. euroneuro.2009.12.003
106. Kavey. Antidepressant psychotherapeutic agents for treatment of chronic insomnia. US5643897; 1997
107. Kavey. Doxepin, amitriptyline, trimipramine, and trazodone for treatment of transient and short-term insomnia. US6211229; 2001
108. Somaxon Pharmaceuticals. Low-dose doxepin for treatment of sleep disorders in elderly patients. WO2007136845; 2007
109. Somaxon Pharmaceuticals. Methods of using low-dose doxepin for the improvement of sleep. WO2008085567; 2008
110. Somaxon Pharmaceuticals. Method using low-dose doxepin for the improvement of sleep. US2009042971; 2009
111. 1 and 5-HT2A receptors. WO2009137531;
112. Somaxon Pharmaceuticals. Ultra low dose doxepin and methods of using the same to treat sleep. US2010105614;
113. Singh H, Becker PM. Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Invest Drugs 2007;16:1295-1305
114. Andersohn F, Schade R, Suissa S, et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009;166:591-598
115. Hypnion. Treatment of CNS disorders using CNS target modulators. WO2003032912; 2003
116. Hypnion. Treatment of CNS disorders using CNS target modulators. US7317026; 2008
117. Hypnion. Treatment of CNS disorders using CNS target modulators. US7189757; 2007
118. 1 receptor. J Biol Chem 1999;274:29994-30000
119. Hypnion. Preparation of doxepin analogs as antihistamines used as sleep modulators. US7524864; 2009
120. Hypnion. Doxepin analogs and methods of use thereof. US2005143348; 2005
121. Hypnion. Preparation of doxepin analogs and their use to modulate sleep. US2005171160; 2005
122. Hypnion. Doxepine analogs and methods of use thereof. WO2005058880; 2005
123. Hypnion. Doxepin analogs and methods of use thereof. US7326721; 2008
124. Hypnion. Preparation of doxepin analogs as sleep modulators. US7411069; 2008
125. Hypnion. Quetiapine analogs for the modulation of sleep. US7563785; 2009
126. Hypnion. Loxapine analogs for modulating sleep. US7592333; 2009
127. Hypnion. Olanzapine analogs and methods of use thereof. WO2007022068; 2007
128. Palomer A, Princep M, Guglietta A. Recent advances in the treatment of insomnia. Ann Rep Med Chem 2007;42:63-80
129. Available from: . com/about/news.htm [Accessed 22 May 2010]
130. Bonhaus DW, Bach C, DeSouza A, et al. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2c receptors. Br J Pharmacol 1995;115:622-628
131. Available from: http:/investor.lilly.com/ pipeline/.cfm [Accessed 22 May 2010]
132. Available from: ct2/show/NCT00784875 [Accessed 22 May 2010].
133. 1-antihistamines for the treatment of insomnia. Bioorg Med Chem Lett 2009;19:4380-4384
134. 1-antihistamines for the treatment of insomnia. Bioorg Med Chem Lett 2010;20:2316-2320
135. 1-antihistamines for the treatment of insomnia. Bioorg Med Chem Lett 2010;20:2629-2633
136. 1-antihistamines for insomnia. Bioorg Med Chem Lett 2010;20:2916-2919
137. 1 binding ligands for inducing sleep. WO2005097093; 2005
138. 1 receptor antagonists as sleep-inducing compounds. WO2006049497; 2006
139. 1 receptor and their stereoselective preparation, pharmaceutical compositions and use in the treatment of sleep disorders. WO2009016084; 2009
140. 1 receptor and their asymmetric preparation, pharmaceutical compositions and use in the treatment of sleep disorders. WO2009016085; 2009
141. 1-Antihistamines in allergic disease. Ed. Simons FER. Chapter 10. New York; 2002. p. 319-336
142. 1-receptor antagonists. J Med Chem 2003;46:5812-5824
143. Jordana M, Waserman S, Arias K. Treatment and/or prevention of peanut induced anaphylaxis. WO2010020057; 2010